Chair and Clinical Professor, Department of Pharmacy and Health Systems Sciences, Director of Pharmaceutical Industry Fellowship Program

J. Andrew Orr-Skirvin

Pharmacy & Health Systems Science

Education

Oregon State University, Bachelor of Science in Pharmacy, 1992
University of Texas at Austin, Doctor of Pharmacy, 1995
Southwest Veterans Hospital, Audie Murphy Division, Oncology Speciaility Pharmacy Residency 1995-1996.

Certification

Board Certified Oncology Pharmacist 2000

Specializations

Hematology/Oncology Pharmacy Practice

Research Interests

Supportive care for the cancer patient including: pain management, nausea & vomiting, neutropenic fever, long term complications, growth factor support, etc.

Publications

Skirvin JA, Patel P. Update on FDA approvals and selected investigational agents. Newsletter, Hematology/Oncology Pharmacy Association, HOPA News, Winter 2006;5-7.

Skirvin JA. Chapter 44, Thrombocytopenia. In Tisdale JE, Miller, DA, editors. Drug-Induced Diseases, prevention, detection, and management. American Society of Health-System Pharmacists. Bethesda, MD; 2005:649-60.

Skirvin JA, Lichtman SM: Pharmacokinetic considerations of oral chemotherapy in elderly cancer patients. Drugs Aging 2002;19:25-42.

Skirvin JA. Melanoma: current detection and management strategies. US Pharmacist Health-System edition 2001;Supplement September:17-28.

Skirvin JA, Vemulapalli S, Lichtman SM: Pharmacology of antineoplastic agents in older cancer patients. Oncology Spectrum 2001;2:404-13.

Skirvin JA, Gorowski E, D’Olimpio JT. Promoting in-patient pain management at a university hospital with comprehensive needs assessment. Proceedings of ASCO 2001;20:304b.

Lichtman S, Skirvin JA. Pharmacology of antineoplastic agents in older cancer patients. Oncology 2000;14:1743-55

Skirvin JA, D’Olimpio JT, Gorowski E. Pain assessment survey of adult oncology admissions: a performance improvement project (Abstract). Proceedings of ASCO 2000,19:640a.

Skirvin JA. Topotecan. CancerRX in Cancer Therapeutics 1999;2:121-5.

Stirling A, Kao E, Skirvin J, Hirsch B. Impact of pharmacist-run aminoglycoside once daily program in a tertiary teaching institution (Abstract). Pharmacotherapy 1999;19:517.

Skirvin JA, Lichtman SM, Negri A, et al. Pharmacist intervention program monitoring filgrastim use in hospitalized patients (Abstract 2252). Proceedings of ASCO 1999;18:583a.

Taibbi R, Kao E, Skirvin JA, et al. Development of an performance improvement program to increase the safety of chemotherapy administration (Abstract 2343). Proceedings of ASCO 1999;18:607a.

Stirling A, Kao E, Skirvin J, Hirsch B. Impact of pharmacist-run aminoglycoside once daily program in a tertiary teaching institution (Abstract). Pharmacotherapy 1999;19:517.

Castanheira D, Marzella M, Skirvin JA. Administration of filgrastim in two patients with drug-induced agranulocytosis. Pharmacotherapy 1998;18:1347-51.

Skirvin JA, Relias V. Topoisomerase Inhibitors: 2. Irinotecan. J Oncol Pharm Practice 1998;4:103-16.

Skirvin JA, Valley AW, Relias V, Morris AK. 6-Mercaptopurine hepatoxicity during acute lymphocytic leukemia maintenance therapy. J Oncol Pharm Practice 1998;4:117-20.

Skirvin JA, Brocavich JM. IV Immunoglobulin Therapy in Immunosuppressed Patients. US Pharmacist health-system edition 1998;23:HS-37-48.

Community Service

Service to cancer patients through my clinical practice site.

Contact Information

Office

140 The Fenway, X205

Email

[email protected]

Phone

617-373-4166

Curriculum Vitae